Issuu on Google+

Global Alliance to Eliminate Lymphatic Filariasis


Lymphatic Filariasis: The Disease • A parasitic disease caused

• • • •

by threadlike worms living in the human lymphatic system Transmitted by mosquitoes Endemic in 83 countries 1.2 billion people at risk More than 120 million people infected – More than 25 million men suffer from genital disease – More than 15 million people suffer from lymphoedema or elephantiasis of the leg


Lymphatic Filariasis or “Elephantiasis”

• A major cause of •

permanent disability and disfigurement Adult worms damage the lymphatic system, causing fluid to collect and cause swelling Patients are physically incapacitated


A Disease of Poverty • LF occurs primarily in poor •

• •

communities The disease exacerbates poverty by physically incapacitating people, thus affecting their livelihood Lost productivity caused by LF disease costs billions of dollars across the world each year Medical treatment for the disease imposes a tremendous burden on individuals and health care systems


Lymphatic Filariasis and Children • Infection acquired in childhood • Often with as many as 1/3 of •

children infected before age 5 Because of the long latency period of the disease, visible symptoms usually appear in puberty Of all LF sufferers, children will benefit most from the elimination programme


Elimination Strategy • Elimination of LF and relief of current affliction through a 2-pronged approach 1. Interrupt Transmission 2. Alleviate and prevent disability


Elimination Strategy Interrupt transmission • Annual treatment of entire populations at risk with donated or inexpensive medicines – albendazole +Mectizan ® (ivermectin) – albendazole + diethylcarbamazine (DEC) – DEC-fortified salt

• Must be treated for at least 5 years


Elimination Strategy Alleviate and prevent disability

• Community-level care for those with disease – Lymphoedema management – Prevention of acute inflammatory episodes – Hydrocele repair


Global Alliance to Eliminate Lymphatic Filariasis

• National Ministries of Health of LF endemic countries International Organizations Private Sector

• • • International Development Agencies and • •

Foundations Non-governmental Organizations Academic & Research Institutions


Total Number of People Treated (by year) 45 40

Number of country programs

250

35 30 25 20 15 10

200 150 100 50

5 0

0 2000

2001

2002

2003

2004

Country programs Treatments administered (both single and dual drug)

Number of treatments administered (millions)

300


Total Population Treated in 2004 (in millions) 250 million treatments in 39 countries

Africa 21.2 M Eastern Americas 1.5 M Mediterranean 2.7 M Mekong Plus 9.4 M PacCARE 1.1 M

South-East Asia 214.1 M


Integration and Synergy Opportunities for cost-effective integration with other communitybased health initiatives:

•Onchocerciasis •Schistosomiasis •School-based deworming •Trachoma •Malaria bed nets •Vitamin A supplements •National Immunization Days


A Future Free of Lymphatic Filariasis Through annual, cost-effective treatments, lymphatic filariasis can be eliminated from the world.

• The communities are ready • The tools are available • More partners and support will make the goal a reality


LFpresentation